Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019

First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors New Preclinical Data Evaluating AMG 757 to Highlight Half-Life Extended BiTE® Immunotherapy AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. "At Amgen, we are searching for and finding answers to incredibly complex questions to advance care and im...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news